Home > Genisphere Appoints New CEO, Thomas Bliss
News & Events

Genisphere Appoints New CEO, Thomas Bliss

Bio-Technology Company Strengthens Operating Team
HATFIELD, Pa -
June 30, 2015 -

Genisphere announced Tom Bliss has joined the company as CEO to help further develop Genisphere’s therapeutics capabilities and portfolio. Mr. Bliss comes with a wealth of partnering experience, having spent much of the last 25 years in leadership positions at bio-pharmaceutical companies including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started his career in Investment Banking, with a focus on Technology and Biotech Corporate Finance. He graduated from Dartmouth College with a BA in English and Asian Studies (Mandarin), and completed his MBA at The Wharton School, University of Pennsylvania in Finance and Marketing.

Tom joins Genisphere as the Company pivots to focus more resources on its emerging therapeutic portfolio, having established its diagnostics business with key strategic partners. “I am excited to start a new challenge with Genisphere, and look forward to working with the team to develop and expand their pharmaceutical collaborations. I know Genisphere has already had substantial success demonstrating our unique 3DNA technology and I’m sure success will accelerate as additional data are generated.”

Dr. Robert Getts, Chief Science Officer, commented “Tom’s wealth of experience and industry knowledge has already made him a key addition to the Genisphere family. Our new innovations led us to look for an experienced leader for our team who will fit in with the company culture, and I’m sure he will make immediate positive contributions.” James Kadushin, Chief Operating Officer, said “I look forward to working with Tom. It is very fortunate that we were able to find someone with deep pharmaceutical development and partnering experience to fulfill this role.”

About Genisphere

Genisphere LLC is the provider of the 3DNA® platform for targeted drug delivery. 3DNA® is a nanoscale, multivalent scaffold made from proprietary, synthetic DNA formed in a flexible, branched structure. 3DNA® nanocarriers are engineered and cross-linked to form a stable architecture while maintaining the biocompatibility of the nucleic-acid building blocks, and demonstrate efficacy and safety with a variety of drug cargos across multiple indications. Genisphere's technology is IP-protected and fully customizable to deliver small molecules, biologics, and nucleic acids with precise specificity enabled by multivalent targeting via antibodies, peptides and other molecular entities. Genisphere leverages a collaborative model to advance its 3DNA® drug delivery platform, and seeks additional partnerships with biotechnology and pharmaceutical companies to improve efficacy and reduce toxicity. Genisphere is also advancing its own lead compounds based on 3DNA® nanotechnology. For more information, please visit http://genisphere.com.

For more information contact:

Tom Bliss
Genisphere
215-996-3027
Tom_Bliss@genisphere.com